177 related articles for article (PubMed ID: 33414909)
1. Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis.
Iwasaki H; Toda S; Murayama D; Kato S; Matsui A
Mol Clin Oncol; 2021 Feb; 14(2):28. PubMed ID: 33414909
[TBL] [Abstract][Full Text] [Related]
2. Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea.
Kim SY; Kim SM; Chang H; Kim BW; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2019; 10():384. PubMed ID: 31244783
[No Abstract] [Full Text] [Related]
3. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.
Capdevila J; Newbold K; Licitra L; Popovtzer A; Moreso F; Zamorano J; Kreissl M; Aller J; Grande E
Cancer Treat Rev; 2018 Sep; 69():164-176. PubMed ID: 30032061
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study.
Iwasaki H; Yamazaki H; Takasaki H; Suganuma N; Nakayama H; Toda S; Masudo K
Oncol Lett; 2018 Dec; 16(6):7271-7277. PubMed ID: 30546466
[TBL] [Abstract][Full Text] [Related]
5. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
[TBL] [Abstract][Full Text] [Related]
6. Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis.
Yu ST; Ge JN; Luo JY; Wei ZG; Sun BH; Lei ST
Cancer Manag Res; 2019; 11():1525-1532. PubMed ID: 30863162
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib for Anaplastic Thyroid Cancer.
Tahara M; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Sasaki T; Suzuki T; Fujino K; Dutcus CE; Takahashi S
Front Oncol; 2017; 7():25. PubMed ID: 28299283
[TBL] [Abstract][Full Text] [Related]
8. The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer.
Jerkovich F; García Falcone MG; Pitoia F
Endocrine; 2019 Jun; 64(3):632-638. PubMed ID: 30820748
[TBL] [Abstract][Full Text] [Related]
9. Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study.
Iwasaki H; Yamazaki H; Takasaki H; Suganuma N; Sakai R; Nakayama H; Toda S; Masudo K
Medicine (Baltimore); 2019 Oct; 98(42):e17588. PubMed ID: 31626129
[TBL] [Abstract][Full Text] [Related]
10. Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer.
Kim M; Ahn J; Song DE; Yoon JH; Kang HC; Lim DJ; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim BH
Endocrine; 2021 Feb; 71(2):427-433. PubMed ID: 32729092
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
Fleeman N; Houten R; Chaplin M; Beale S; Boland A; Dundar Y; Greenhalgh J; Duarte R; Shenoy A
BMC Cancer; 2019 Dec; 19(1):1209. PubMed ID: 31830943
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice.
Berdelou A; Borget I; Godbert Y; Nguyen T; Garcia ME; Chougnet CN; Ferru A; Buffet C; Chabre O; Huillard O; Leboulleux S; Schlumberger M
Thyroid; 2018 Jan; 28(1):72-78. PubMed ID: 29048237
[No Abstract] [Full Text] [Related]
13. Ten years' real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer.
Jerkovich F; Capalbo S; Abelleira E; Pitoia F
Endocrine; 2024 May; ():. PubMed ID: 38772990
[TBL] [Abstract][Full Text] [Related]
14. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
15. Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer.
Su X; Liu J; Zhang H; Gu Q; Zhou X; Ji M; Yao D
Onco Targets Ther; 2020; 13():11183-11192. PubMed ID: 33173310
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
17. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction.
Koyama S; Miyake N; Fujiwara K; Morisaki T; Fukuhara T; Kitano H; Takeuchi H
Eur Thyroid J; 2018 Jun; 7(3):139-144. PubMed ID: 30023346
[TBL] [Abstract][Full Text] [Related]
19. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer.
Valerio L; Giani C; Agate L; Molinaro E; Viola D; Bottici V; Matrone A; Puleo L; Lorusso L; Cappagli V; Ribechini A; Elisei R
Eur Thyroid J; 2021 Jul; 10(5):399-407. PubMed ID: 34540710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
